AML management now hinges on molecularly defined subtypes, supported by numerous targeted approvals; expanding trial access ...
Earlier, systematic supportive and palliative integration, plus streamlined logistics and clearer counseling on novel-therapy AE profiles, could reduce household disruption during treatment and ...
As discussed at a recent IVBM event, Robert Kratzke, MD, outlines essential biomarkers, NGS panel selection, and next steps ...
National health spending is forecast to approach $9 trillion by 2034, increasing faster than GDP and consuming 20.6% of the ...
Deloitte's Pete Lyons explains the confidence gap, diverging biopharmaceutical and medical technology risks, and what separates real AI value from activity. 259 Prospect Plains Rd, Bldg H Cranbury, NJ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results